Cixutumumab
Information
- Drug Name
- Cixutumumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| Ewing sarcoma of bone |
PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 4 | 23800680 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Report of complete response to IGF1-R antibody, wi... | PTPRD |
PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) PTPRD p.Val253Ile (p.V253I) ( ENST00000355233.9, ENST00000356435.9, ENST00000381196.9, ENST00000397606.7, ENST00000397611.7, ENST00000397617.8, ENST00000486161.5, ENST00000537002.5, ENST00000540109.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01142388 | Active, not recruiting | Phase 2 | Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | September 21, 2010 | March 7, 2025 |
| NCT00617708 | Completed | Phase 1/Phase 2 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | March 2008 | February 25, 2014 |
| NCT00639509 | Completed | Phase 2 | IMC-A12 in Treating Patients With Advanced Liver Cancer | March 2008 | February 2011 |
| NCT00678769 | Completed | Phase 1 | Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer | May 2008 | October 2015 |
| NCT00684983 | Completed | Phase 2 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | July 30, 2008 | October 15, 2019 |
| NCT00699491 | Completed | Phase 1/Phase 2 | Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | October 31, 2008 | February 14, 2018 |
| NCT00720174 | Completed | Phase 1 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | June 2008 | |
| NCT00778167 | Completed | Phase 1/Phase 2 | Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | October 2008 | May 2012 |
| NCT00781911 | Completed | Phase 2 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | February 2009 | May 2016 |
| NCT00831844 | Completed | Phase 2 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | January 2009 | October 2013 |
| NCT00880282 | Completed | Phase 1 | Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment | April 2009 | |
| NCT00887159 | Completed | Phase 2 | A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | July 16, 2009 | November 15, 2016 |
| NCT00986674 | Completed | Phase 2 | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | September 2009 | December 2013 |
| NCT01007032 | Completed | Phase 1 | A Study of IMC-A12 in Advanced Solid Tumors | November 2009 | April 2015 |
| NCT01008566 | Completed | Phase 1 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | August 2009 | |
| NCT01016015 | Completed | Phase 2 | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | November 2009 | July 2014 |
| NCT01026623 | Completed | Phase 1/Phase 2 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | October 2009 | February 2013 |
| NCT01055314 | Completed | Phase 2 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | January 2010 | June 2016 |
| NCT01061749 | Completed | Phase 1 | Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | November 2009 | September 2014 |
| NCT01120236 | Completed | Phase 2 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | December 2010 | August 23, 2017 |
| NCT01614795 | Completed | Phase 2 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | June 18, 2012 | April 1, 2014 |
| NCT00609141 | Completed | Phase 1 | IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor | January 2008 | |
| NCT01204476 | Completed | Phase 1 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | October 2010 | |
| NCT01232452 | Completed | Phase 2 | A Study in Non-Small Cell Lung Cancer | April 2011 | June 2016 |
| NCT01263782 | Completed | Phase 2 | BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | May 17, 2011 | August 15, 2017 |
| NCT01413191 | Completed | Phase 2 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | August 2011 | June 2014 |
| NCT00955305 | Terminated | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | March 2010 | November 2016 |